Free tool
FAERS Monitor: Beyaz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022532 or its brand name (Beyaz, Drospirenone, Ethinyl Estradiol, Levomefolate Calcium). Reports on generic versions are filed under their own applications.
Reports
1,626
Serious
772
47% of reports
Hospitalization
456
Death reported
22
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pulmonary embolism310
- deep vein thrombosis243
- injury236
- pain205
- emotional distress163
- anxiety148
- drug dose omission97
- no adverse event97
- general physical health deterioration93
- anhedonia84
- metrorrhagia76
- nausea69
- dyspnoea63
- thrombosis59
- headache58
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 332 |
| 2012 | 457 |
| 2013 | 360 |
| 2014 | 164 |
| 2015 | 95 |
| 2016 | 83 |
| 2017 | 37 |
| 2018 | 24 |
| 2019 | 11 |
| 2020 | 18 |
| 2021 | 17 |
| 2022 | 5 |
| 2023 | 9 |
| 2024 | 4 |
| 2025 | 5 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,533 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| metrorrhagiaSignal | 76 | 57.9 | 46.5 | 4,178 |
| deep vein thrombosisSignal | 243 | 48.6 | 43.2 | 11,262 |
| injurySignal | 236 | 43.6 | 38.7 | 9,772 |
| pulmonary embolismSignal | 310 | 42.3 | 38.3 | 12,484 |
| anhedoniaSignal | 84 | 41.5 | 33.7 | 3,271 |
| emotional distressSignal | 163 | 17.4 | 15.1 | 2,520 |
| general physical health deteriorationSignal | 93 | 10.4 | 8.5 | 785 |
| thrombosisSignal | 59 | 9.5 | 7.4 | 441 |
| drug dose omissionSignal | 97 | 7.6 | 6.3 | 553 |
| no adverse eventSignal | 97 | 6.9 | 5.7 | 490 |
| anxietySignal | 148 | 6.7 | 5.8 | 726 |
| painSignal | 205 | 4.3 | 3.8 | 535 |
| dyspnoea | 63 | 1.4 | 1.1 | 8 |
| headache | 58 | 1.2 | 0.9 | 2 |
| nausea | 69 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.